Standard pediatric heart failure regimens were employed in these infants and young children, including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), β-blockers, and mineralocorticoid receptor antagonists, with regular monitoring of blood pressure, cardiac function, and electrolyte balance. This evidence concerns the gene NR3C2 and heart failure.